Pipeline
Pipeline Overview
We have assembled a robust portfolio of allogeneic, iPSC-derived cell therapies for type 1 diabetes and other autoimmune diseases. All our product candidates have been engineered with our novel, proprietary immune evasion technology, called Allo-Evasion™, to avoid host rejection and potentially increase the durability of clinical responses.
- Product
- CNTY-813 Islet cells (Allo-Evasion™ 5.0)
- Targets
- Islet Transplantation
- Indications
- Type 1 diabetes
- Development progress
- Product
- CNTY-308 αβ CAR-iT (Allo-Evasion™ 5.0)
- Targets
- CD19
- Indications
- B-cell-mediated autoimmune diseases
- Development progress
- Product
- Multiple (Allo-Evasion™ 5.0)
- Targets
- Multiple
- Indications
- Not disclosed
- Development progress
| Product | Targets | Indications | Research | IND-enabling | Clinical |
|---|---|---|---|---|---|
| Priority Program | |||||
| CNTY-813 Islet cells (Allo-Evasion™ 5.0) | Islet Transplantation | Type 1 diabetes |
|
||
| Additional Programs1 | |||||
| CNTY-308 αβ CAR-iT (Allo-Evasion™ 5.0) | CD19 | B-cell-mediated autoimmune diseases |
|
||
| Multiple (Allo-Evasion™ 5.0) | Multiple | Not disclosed |
|
||
1. Agreement in place for an ongoing investigator sponsored trial (IST) for CNTY-101 by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.
CNTY-813
CNTY-813 is an islet replacement therapy engineered with Allo-Evasion™ 5.0 to protect from T cell, NK cell and humoral immune rejection, designed to deliver durable glycemic control in patients with type 1 diabetes without the need for chronic immunosuppression.
CNTY-308
CNTY-308 is a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, designed to be functionally comparable to primary T cells for the potential treatment for B-cell-mediated autoimmune diseases.
Additional Programs
Our early-stage pipeline includes other iPSC-derived cell therapies that are designed to address diseases where current gaps in care leave opportunities for cell therapies, when engineered with Allo-EvasionTM, to make meaningful impact in patient lives.